OXY-6-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290. MLKSSWRKSALMAAAAVPLLLASGSLWASADAIQQKLADLEKRSGGRLGVALINTADDSQTLYRGDERFAMCSTGKVMAAAAVLKQSESHPDVVNKRLEIKKSDLVVWSPITEKHLQSGMTLAELSAAALQYSDNTAMNKMISYLGGPEKVTAFAQSIGDVTFRLDRTEPALNSAIPGDKRDTTTPLAMAESLRKLTLGNALGEQQRAQLVTWLKGNTTGGQSIRAGLPASWAVGDKTGAGDYGTTNDIAVIWPENHAPLVLVTYFTQPQQDAKSRKEVLAAAAKIVTEGL

OXY-6-2	.............-.....................................................................................................................................................................................................................................................................................	99.66 %
OXY-6-3	.......................................................T...........................................................................................................................................................................................................................................	99.66 %
OXY-6-4	......................................N............................................................................................................................................................................................................................................................	99.66 %
OXY-6-5	.............-........................................................................................................................................................................................................................N............................................................	99.31 %
OXY-6-6	.....................................TN......................................................L.....................................................................................................................................................................................................	98.97 %
OXY-6-7	......................................N......................................................L.....................................................................................................................................................................................................	99.31 %
OXY-6-8	...................................................................................................................P...............................................................................................................................................................................	99.66 %
OXY-6-9	......................................N...........................................................................................................................................................................................D................................................................	99.31 %
OXY-6-10	......................................N...............................................................................................................................................................V............................................................................................	99.31 %
OXY-6-11	..................................................................................................................................................................................................................M................................................................................	99.66 %

Last updated: November 20, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)